Literature DB >> 9420273

Extent of antigenic diversity in the V3 region of the surface glycoprotein, gp120, of human immunodeficiency virus type 1 group M and consequences for serotyping.

J C Plantier1, S Le Pogam, F Poisson, L Buzelay, B Lejeune, F Barin.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) may be studied by molecular or immunological approaches. Most analyses have been performed by genetic comparison of isolates and have led to the definition of clades or subtypes within the major (M) group of HIV-1. Five subtypes (A to E) were initially identified by comparison of genomic sequences. Four new subtypes (F to I) were identified more recently. Amino acid differences in the immunogenic V3 loop between isolates have also been studied, leading to a phenetic classification of at least 14 clusters (1 to 14) of sequences (B. T. M. Korber, K. McInnes, R. F. Smith, and G. Myers, J. Virol. 68:6730-6744, 1994). In this study, we compared the antigenicity of the V3 consensus sequences defined by phylogenetic analysis to the antigenicity of those defined by phenetic analysis. We used a recently developed subtype-specific enzyme immunoassay (SSEIA) that uses the principle of blocking with an excess of peptide in the liquid phase. Two SSEIAs were performed, the first with five V3 sequences defined by phylogenetic analysis and the second with 14 V3 sequences defined by phenetic analysis. A total of 168 HIV-1 sera taken from seropositive individuals from seven different countries or regions were studied. Experimental and statistical data, including correlation matrix and cluster analyses, demonstrated associations between the genetic subtypes and phenetically associated groups. Most of these were predicted by Korber et al. (J. Virol. 68:6730-6744, 1994) by theoretical analysis. We also found that V3 sequences can be grouped into between three and five antigenically unrelated categories. Residues that may be responsible for major antigenic differences were identified at the apex of the V3 loop, within the octapeptide xIGPGxxx, where x represents the critical positions. Our study provides evidence that there is a limited number of V3 serotypes which could be easily monitored by serological assays to study the diversity and dynamics of HIV-1 strains.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9420273      PMCID: PMC109422     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Genetic variants of HIV-1 in Thailand.

Authors:  F E McCutchan; P A Hegerich; T P Brennan; P Phanuphak; P Singharaj; A Jugsudee; P W Berman; A M Gray; A K Fowler; D S Burke
Journal:  AIDS Res Hum Retroviruses       Date:  1992-11       Impact factor: 2.205

2.  Development of hydrophobicity parameters to analyze proteins which bear post- or cotranslational modifications.

Authors:  S D Black; D R Mould
Journal:  Anal Biochem       Date:  1991-02-15       Impact factor: 3.365

3.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

4.  Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.

Authors:  G J LaRosa; J P Davide; K Weinhold; J A Waterbury; A T Profy; J A Lewis; A J Langlois; G R Dreesman; R N Boswell; P Shadduck
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

5.  HIV-1 strains from India are highly divergent from prototypic African and US/European strains, but are linked to a South African isolate.

Authors:  U Dietrich; M Grez; H von Briesen; B Panhans; M Geissendörfer; H Kühnel; J Maniar; G Mahambre; W B Becker; M L Becker
Journal:  AIDS       Date:  1993-01       Impact factor: 4.177

6.  Greater diversity of the HIV-1 V3 neutralization domain in Tanzania compared with The Netherlands: serological and genetic analysis.

Authors:  G Zwart; T F Wolfs; R Bookelman; S Hartman; M Bakker; C A Boucher; C Kuiken; J Goudsmit
Journal:  AIDS       Date:  1993-04       Impact factor: 4.177

7.  Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  M K Gorny; J Y Xu; V Gianakakos; S Karwowska; C Williams; H W Sheppard; C V Hanson; S Zolla-Pazner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

8.  Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen.

Authors:  J M Rini; R L Stanfield; E A Stura; P A Salinas; A T Profy; I A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

9.  HIV-1 and HIV-2 infections in a high-risk population in Bombay, India: evidence for the spread of HIV-2 and presence of a divergent HIV-1 subtype.

Authors:  A Pfützner; U Dietrich; U von Eichel; H von Briesen; H D Brede; J K Maniar; H Rübsamen-Waigmann
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992-10

10.  Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody.

Authors:  M K Gorny; A J Conley; S Karwowska; A Buchbinder; J Y Xu; E A Emini; S Koenig; S Zolla-Pazner
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

View more
  5 in total

1.  Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV.

Authors:  S Zolla-Pazner; M K Gorny; P N Nyambi; T C VanCott; A Nádas
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.

Authors:  Chavdar Krachmarov; Abraham Pinter; William J Honnen; Miroslaw K Gorny; Phillipe N Nyambi; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots.

Authors:  Francis Barin; Laurence Meyer; Rémi Lancar; Christiane Deveau; Myriam Gharib; Anne Laporte; Jean-Claude Desenclos; Dominique Costagliola
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

5.  Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.

Authors:  P N Nyambi; A Nádas; H A Mbah; S Burda; C Williams; M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.